Improved Conjugation, 64-Cu Radiolabeling, in Vivo Stability, and Imaging Using Nonprotected Bifunctional Macrocyclic Ligands: Bis(Phosphinate) Cyclam (BPC) Chelators.
Tomáš DavidVeronika HlinováVojtěch KubíčekRalf BergmannFranziska StrieseNicole BerndtDávid SzöllősiTibor KovácsDomokos MáthéMichael BachmannHans-Jürgen PietzschPetr HermannPublished in: Journal of medicinal chemistry (2018)
Bifunctional derivatives of bis(phosphinate)-bearing cyclam (BPC) chelators bearing a carboxylate, amine, isothiocyanate, azide, or cyclooctyne in the BP side chain were synthesized. Conjugations required no protection of phosphinate or ring secondary amine groups. The ring amines were not reactive (proton protected) at pH < ∼8. For isothiocyanate coupling, oligopeptide N-terminal α-amines were more suitable than alkyl amines, e.g., Lys ω-amine (p Ka ∼7.5-8.5 and ∼10-11, respectively) due to lower basicity. The Cu-64 labeling was efficient at room temperature (specific activity ∼100 GBq/μmol; 25 °C, pH 6.2, ∼100 ligand equiv, 10 min). A representative Cu-64-BPC was tested in vivo showing fast clearance and no nonspecific radioactivity deposition. The monoclonal anti-PSCA antibody 7F5 conjugates with thiocyanate BPC derivative or NODAGA were radiolabeled and studied in PC3-PSCA tumor bearing mice by PET. The radiolabeled BPC conjugate was accumulated in the prostate tumor with a low off-target uptake, unlike Cu-64-labeled NODAGA-antibody conjugate. The BPC chelators have a great potential for theranostic applications of the Cu-64/Cu-67 matched pair.
Keyphrases
- room temperature
- metal organic framework
- ionic liquid
- aqueous solution
- prostate cancer
- high resolution
- cancer therapy
- computed tomography
- photodynamic therapy
- type diabetes
- pet imaging
- drug delivery
- fluorescence imaging
- highly efficient
- mass spectrometry
- benign prostatic hyperplasia
- high fat diet induced
- human health